NCT06849973 - To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome | Biotech Hunter

Enrollment

187

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

November 22, 2024

Study Completion Date

January 28, 2025

Conditions

Rett Syndrome

Interventions

DRUG

Drug: Bionetide

NA-921 (Bionetide) solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

DRUG

Placebo

NA-921 (Bionetide) placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

Trial Locations (16)

2050

Biomed Research Unit-BIO-16-NSW, Camperdown

2060

Biomed Research Unit-BIO-15, Sydney

3010

Biomed Research Unit- BIO-14-VIC 3010, Parkville

3084

Biomed Research Unit-BIO-13-VIC-3084 Heidelberg West, Victoria, Australia, 3084, Heidelberg West

10467

Biomed Testing Facility #BIO-9-10467, The Bronx

21205

Maryland Locations Biomed Testing Facility #BIO-7-21205, Baltimore

44195

Biomed Testing Facility #BIO-10-44195, Cleveland

60612

Biomed Testing Facility #BIO-06-60612, Chicago

77030

Biomed Testing Facility #BIO-11-77030, Houston

80042

Biomed Testing Facility #BIO-05-80042, Aurora

90095

Biomed Testing Facility # BIO-03-90095, Los Angeles

92093

Biomed Testing Facility # BIO-04-92093, La Jolla

94104

Biomed Testing Facility # BIO-01-94104, San Francisco

95817

Biomed Testing Facility # BIO-02-95817, Sacramento

98105

Biomed Testing Facility #BIO-12-98105, Seattle

02115

Biomed Testing Facility #BIO-8-02115, Boston

All Listed Sponsors

lead

Biomed Industries, Inc.

INDUSTRY